Abstract: This invention provides Chelating Complex Micelles as a drug carrier. The Chelating Complex Micelles can load drugs without changing their structure, and therefore extend the half-life of drugs in the human body. The chelating complex micelles contain a metal ion core, at least one polymer, and at least one drug molecule. The metal ion is considered as a Lewis acid while polymer chain and drug molecules are referred to as Lewis bases. The drug molecule is linked to the polymer via forming coordinate bonds with metal ion, and then self-assembled to form chelating complex micelles as a drug carrier.

Abstract: This invention provides Chelating Complex Micelles as a drug carrier. The Chelating Complex Micelles can load drugs without changing their structure, and therefore extend the half-life of drugs in the human body. The chelating complex micelles contain a metal ion core, at least one polymer, and at least one drug molecule. The metal ion is considered as a Lewis acid while polymer chain and drug molecules are referred to as Lewis bases. The drug molecule is linked to the polymer via forming coordinate bonds with metal ion, and then self-assembled to form chelating complex micelles as a drug carrier.

Abstract: This invention provides Chelating Complex Micelles as a drug carrier. The Chelating Complex Micelles can load drugs without changing their structure, and therefore extend the half-life of drugs in the human body. The chelating complex micelles contain a metal ion core, at least one polymer, and at least one drug molecule. The metal ion is considered as a Lewis acid while polymer chain and drug molecules are referred to as Lewis bases. The drug molecule is linked to the polymer via forming coordinate bonds with metal ion, and then self-assembled to form chelating complex micelles as a drug carrier.

Abstract: The present invention provides an insulation film, comprising a film upper layer (101) and a film lower layer (103), wherein both of the film upper layer (101) and film lower layer (103) are made of a PC or PET material, the PC or PET material contains a flame retardant to meet the flame retardance thereof; a film intermediate layer (102) located between the film upper layer and the film lower layer, the film intermediate layer (102) is made of a PC or PET material, the PC or PET material does not contain a flame retardant or contains a small amount of halogen-free flame retardant; an upper surface of the film intermediate layer (102) is bound together with a lower surface of the film upper layer (101), a lower surface of the film intermediate layer (102) is bound together with an upper surface of the film lower layer (103).

Abstract: The present invention provides an insulation film (100), comprising a film upper layer (101) and a film lower layer (103), wherein both of the film upper layer (101) and film lower layer (103) are made of a PC or PET material, the PC or PET material contains a flame retardant to meet the flame retardance and puncture resistance property thereof; a film intermediate layer (102) located between the film upper layer (101) and the film lower layer (103), the film intermediate layer (102) is made of the blends of PP and/or PE and PC and/or PET; an upper surface of the film intermediate layer (102) is bound together with a lower surface of the film upper layer (101), a lower surface of the film intermediate layer (102) is bound together with an upper surface of the film lower layer (103).

Abstract: The present invention features a pharmaceutical composition used for reducing the damage caused by free radicals, which comprises at least a metal or its ions, at least a drug or an antioxidant that is carrier-protected/modified, and a drug carrier. Said carrier helps to preserve the anti-oxidative activity, and hence, prevents the decrease of the effect of the antioxidant against free radicals produced in the environment or body fluids and prolongs protection, and may be used for reducing damage caused by radiation and adverse effects induced by chemotherapeutic drugs.

Abstract: The NVM device includes a semiconductor substrate having a first region and a second region. The NVM device includes a data-storing structure formed in the first region and designed operable to retain charges. The NVM device includes a capacitor formed in the second region and coupled with the data-storing structure for data operations. The data-storing structure includes a first doped well of a first-type in the semiconductor substrate. The data-storing structure includes a first gate dielectric feature on the first doped well. The data-storing structure includes a first gate electrode disposed on the first gate dielectric feature and configured to be floating. The capacitor includes a second doped well of the first-type. The capacitor includes a second gate dielectric feature on the second doped well. The capacitor also includes a second gate electrode disposed on the second gate dielectric feature and connected to the first gate electrode.

Abstract: A foldable air cushioned structure formed by two outer films, comprises a plurality of heat-sealing lines, air cylinders, nodes and clasp points. The heat-sealing lines are arranged in order for attaching parts of two outer films. The air cylinders are positioned between heat-sealing lines. The nodes are formed inside the air cylinders for attaching parts of the inner surfaces of two outer films, and arranged in lines perpendicular to the heat-sealed lines to form foldable lines. The clasp points are formed on the outer surface of two outer films for attaching parts of the outer surfaces of two outer films. After folding the air cylinder along the folding lines, the air cylinders forms two side portions, at least one supporting portion, and at least two bottom portions. The supporting portion forms at least one convex for supporting an object by the pressure along the long-axis of the air cylinder.

Abstract: The NVM device includes a semiconductor substrate having a first region and a second region. The NVM device includes a data-storing structure formed in the first region and designed operable to retain charges. The NVM device includes a capacitor formed in the second region and coupled with the data-storing structure for data operations. The data-storing structure includes a first doped well of a first-type in the semiconductor substrate. The data-storing structure includes a first gate dielectric feature on the first doped well. The data-storing structure includes a first gate electrode disposed on the first gate dielectric feature and configured to be floating. The capacitor includes a second doped well of the first-type. The capacitor includes a second gate dielectric feature on the second doped well. The capacitor also includes a second gate electrode disposed on the second gate dielectric feature and connected to the first gate electrode.

Abstract: The NVM device includes a semiconductor substrate having a first region and a second region. The NVM device includes a data-storing structure formed in the first region and designed operable to retain charges. The NVM device includes a capacitor formed in the second region and coupled with the data-storing structure for data operations. The data-storing structure includes a first doped well of a first-type in the semiconductor substrate. The data-storing structure includes a first gate dielectric feature on the first doped well. The data-storing structure includes a first gate electrode disposed on the first gate dielectric feature and configured to be floating. The capacitor includes a second doped well of the first-type. The capacitor includes a second gate dielectric feature on the second doped well. The capacitor also includes a second gate electrode disposed on the second gate dielectric feature and connected to the first gate electrode.

Abstract: This invention provides Chelating Complex Micelles as a drug carrier. The Chelating Complex Micelles can load drugs without changing their structure, and therefore extend the half-life of drugs in the human body. The chelating complex micelles contain a metal ion core, at least one polymer, and at least one drug molecule. The metal ion is considered as a Lewis acid while polymer chain and drug molecules are referred to as Lewis bases. The drug molecule is linked to the polymer via forming coordinate bonds with metal ion, and then self-assembled to form chelating complex micelles as a drug carrier.

Abstract: This invention provides Chelating Complex Micelles as a drug carrier. The Chelating Complex Micelles can load drugs without changing their structure, and therefore extend the half-life of drugs in the human body. The chelating complex micelles contain a metal ion core, at least one polymer, and at least one drug molecule. The metal ion is considered as a Lewis acid while polymer chain and drug molecules are referred to as Lewis bases. The drug molecule is linked to the polymer via forming coordinate bonds with metal ion, and then self-assembled to form chelating complex micelles as a drug carrier.

Abstract: This invention provides Chelating Complex Micelles as a drug carrier. The Chelating Complex Micelles can load drugs without changing their structure, and therefore extend the half-life of drugs in the human body. The chelating complex micelles contain a metal ion core, at least one polymer, and at least one drug molecule. The metal ion is considered as a Lewis acid while polymer chain and drug molecules are referred to as Lewis bases. The drug molecule is linked to the polymer via forming coordinate bonds with metal ion, and then self-assembled to form chelating complex micelles as a drug carrier.

Abstract: The present disclosure provides a bio-field effect transistor (BioFET) and a method of fabricating a BioFET device. The method includes forming a BioFET using one or more process steps compatible with or typical to a complementary metal-oxide-semiconductor (CMOS) process. The BioFET device includes a substrate, a transistor structure having a treated layer adjacent to the channel region, an isolation layer, and a dielectric layer in an opening of the isolation layer on the treated layer. The dielectric layer and the treated layer are disposed on opposite side of the transistor from a gate structure. The treated layer may be a lightly doped channel layer or a depleted layer.

Abstract: A protecting structure of an uninterruptible power supply prevents the uninterruptible power supply. The uninterruptible power supply device has a switch with a switching piece. The protecting structure includes a chassis, a sensor and a cover body. The chassis has an opening slot, the uninterruptible power supply device is installed in the chassis, and the switching piece is disposed corresponding to the opening slot. The sensor is provided on a side of the opening slot of the chassis and electrically connected with the uninterruptible power supply device. The cover body includes a cover plate and at least one blocking member connecting with the cover plate. The cover plate covers the opening slot, wherein the switching piece ejects the blocking member to expose the opening slot when the covered switching piece is switched from a first position to a second position.

Abstract: This invention provides the controlled-release method for a pharmaceutical composition comprising of metals in the drug carrier. The specific chelator is used to trigger the release of active pharmaceutical ingredients from chelating complex micelles. The drug release rate and half-life can also be controlled by manipulating the dosing sequence and the concentration of metal and specific chelator.

Abstract: The invention provides a method for forming a fermented composition of mung bean hulls, including: mixing mung bean hulls and water to form a mixture; adding a fungus into the mixture, wherein the fungus includes Rhizopus spp. or Aspergillus spp.; and fermenting the mixture to form a fermented composition. The invention also includes a fermented composition of mung bean hulls by the method and an anti-oxidation and anti-inflammation composition containing the fermented composition of mung bean hulls.

Abstract: This invention provides Chelating Complex Micelles as a drug carrier. The Chelating Complex Micelles can load drugs without changing their structure, and therefore extend the half-life of drugs in the human body. The chelating complex micelles contain a metal ion core, at least one polymer, and at least one drug molecule. The metal ion is considered as a Lewis acid while polymer chain and drug molecules are referred to as Lewis bases. The drug molecule is linked to the polymer via forming coordinate bonds with metal ion, and then self-assembled to form chelating complex micelles as a drug carrier.

Abstract: A multi-sectional clamping type air enclosure is constituted by connecting a second, a third, and a fourth air cylinder sheet(s) sequentially in series to a first air cylinder sheet, in which an air filling passageway is disposed in the first air cylinder sheet to allow air to be filled in a plurality of first air cylinders and the second air cylinder sheet(s), the third air cylinder sheet and the fourth air cylinder sheet(s) communicated therewith to be filled with air and expanded. Thereafter, the second air cylinder(s) and the fourth air cylinder sheet(s) are bended toward the third air cylinder sheet to form approximately a U-typed body, and auxiliary air cylinders of the air cylinder sheet are then bended toward main air cylinders of the air cylinder sheet to cause side air cylinders of the air cylinder sheet to be approximately perpendicular to the main air cylinders.

Abstract: A method and system of teaming via a social network service for activity coaching include creating a stage model that comprises a first and second stages, wherein a value of a performing parameter for use in the first stage is less than a value of the performing parameter for use in the second stage; receiving initial activity data of users at social network service; determining users involved in the first stage according to initial activity data; teaming the users involved in the first stage; communicating to users via social network service the value of the performing parameter for use in the second stage; setting a team goal to achieve the value; waiting for feedback from the users; determining whether the team goal is achieved; moving the users in the same team to the second stage; and providing rewards to the users, if the determination is affirmative.